DNA damage resulting in multiple broken chromosomes (Photo credit: Wikipedia)
New research in The FASEB Journal suggests that white blood cells exposed to UVA light in agar, to induce DNA damage, can predict if one has or is at risk for cancer
A new research report published in the October 2014 issue of The FASEB Journal may make the early detection of cancer as easy as a simple blood test. This test, called the “lymphocyte genome sensitivity” (LGS) test, could not only detect some cancers earlier than ever before, but it may eliminate the need for some types of biopsies, as well as identify those more likely to develop cancer in the future.
“The test could allow earlier cancer detection, so helping to save peoples’ lives,” said Diana Anderson, a researcher involved in the work from the School of Life Sciences at the University of Bradford in West Yorkshire, United Kingdom.
To develop this test, Anderson and colleagues took blood samples from a group of people that included healthy individuals, cancer patients and people believed to be at a higher risk than normal to develop cancer. White blood cells (lymphocytes) in these samples were examined in a Comet test, by embedding the cells in a jelly-like substance, called agar, on a microscope slide. In this test, damage to the genetic material (DNA) of the cells was caused by treatment with ultraviolet (UVA) light. This damage was observed in the form of DNA pieces being pulled within the agar in an electric field toward the positive end of the field. This caused a comet-like tail, and the longer the tail the more DNA damage. Different thicknesses of the agar were applied to the slides. In healthy people, as different thicknesses were added, DNA-damaged tail responses returned to normal levels. In cancer patients, DNA-damaged tail responses remained high and in those people who might develop pre-cancerous diseases, tail responses were in between. This means that people with cancer have DNA which is more easily damaged by UVA than do other people, so the test shows the sensitivity to damage of all the genome in a cell. The LGS test has been used to examine blood samples from cancer patients with melanoma, colon cancer and lung cancer, and all gave the same outcomes.
The Latest on: Cancer blood test
via Google News
The Latest on: Cancer blood test
- Midlands Voices: Nebraska can make progress against colon cancer. Here's howon March 6, 2021 at 4:30 am
Yes, colon cancer is preventable, treatable and beatable. But we must get in the game if we want to be on the winning team. Historically, Nebraska has had low screening and high incidence rates. In ...
- Study Shows Simple Blood Test Could Detect Liver Injury Earlieron March 5, 2021 at 9:49 am
Dr. Jie Zheng and his colleagues described how gold nanoparticles may play a key role in a simple blood test to find acute liver damage earlier than current methods.
- What Are the First Signs of Pancreatic Cancer?on March 5, 2021 at 6:00 am
Pancreatic cancer can cause blood to clot more easily ... The doctor can perform tests and procedures to help investigate what may be the cause. "If you have certain risk factors, you may also ...
- A monolithic single-chip point-of-care platform for metabolomic prostate cancer detectionon March 5, 2021 at 1:51 am
With prostate cancer, the absence of a reliable test has inhibited the adoption of screening programs. We report a microelectronic point-of-care metabolite biomarker measurement platform and use it ...
- A two-tiered targeted proteomics approach to identify pre-diagnostic biomarkers of colorectal cancer riskon March 4, 2021 at 9:02 am
Colorectal cancer prognosis is dependent on stage, and measures to improve early detection are urgently needed. Using prospectively collected plasma samples from the population-based Northern Sweden ...
- Agilent to pick up cancer blood tester Resolution Bio in $695M dealon March 4, 2021 at 7:50 am
Diving deeper into the cancer testing market, Agilent Technologies aims to pick up liquid biopsy developer Resolution Bioscience for $550 million in upfront cash.
- Glasgow firm behind pioneering blood test to detect cancer secures seven-figure booston March 4, 2021 at 7:32 am
A Glasgow-based developer of liquid biopsies for the early detection of cancer has reached its round two funding target by securing further investment of more than £1 million – as it eyes Series A ...
- GRAIL Announces First Health System to Offer Galleri, Novel Multi-Cancer Early Detection Blood Teston March 2, 2021 at 5:34 am
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a partnership with leading health system Providence to advance the science and delivery ...
- Chosen wisely: Grail, Quest team up on cancer blood teston February 23, 2021 at 6:45 am
In a gift to your headline writer, Grail has tapped testing giant Quest Diagnostics to help roll out its upcoming multi-cancer blood test.
- GRAIL and Quest Diagnostics Announce Collaboration to Support Galleri, First-of-Kind Multi-Cancer Early Detection Blood Teston February 23, 2021 at 5:30 am
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced an agreement with Quest Diagnostics, the leading provider of diagnostic information ...
via Bing News
